Erratum to: A Functional Role for VEGFR1 Expressed in Peripheral Sensory Neurons in Cancer Pain [Cancer Cell. 2015 27(6):780-96.] DOI: 10.1016/j.ccell.2015.04.017;A Functional Role for VEGFR1 Expressed in Peripheral Sensory Neurons in Cancer Pain

Cancer Cell

Volumn 27, Issue 6, 2015, Pages 780-796

  Selvaraj, Deepitha ^a   Gangadharan, Vijayan ^a   Michalski, Christoph W ^a   Kurejova, Martina ^a   Stösser, Sebastian ^a   Srivastava, Kshitij ^b   Schweizerhof, Matthias ^a   Waltenberger, Johannes ^c,d   Ferrara, Napoleone ^e   Heppenstall, Paul ^f,g   Shibuya, Masabumi ^h,i   Augustin, Hellmut G ^a,b   Kuner, Rohini ^a,g  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f EUROPEAN MOLECULAR BIOLOGY LABORATORY EMBL   (Italy)

^g Otto Meyerhof Centre   (Germany)

^h TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

ⁱ JOBU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINOCICEPTIVE AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DC101; MONOCLONAL ANTIBODY MF 1; NEUTRALIZING ANTIBODY; PLACENTAL GROWTH FACTOR; PLACENTAL GROWTH FACTOR 2; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR;

ANALGESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BONE PAIN; CANCER INHIBITION; CANCER PAIN; CANCER THERAPY; CONTROLLED STUDY; DRUG EFFICACY; GENE DELETION; GENE SILENCING; HUMAN; HUMAN TISSUE; HYPERALGESIA; IN VIVO STUDY; INTRACELLULAR SIGNALING; MEDIATOR RELEASE; NOCICEPTION; NOCICEPTIVE PAIN; NONHUMAN; PAIN ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSORY NERVE CELL; SYSTEMIC THERAPY; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; MALE; METABOLISM; MOUSE; NEOPLASM; PAIN; PATHOLOGY; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MALE; MICE; MICE, INBRED C57BL; NEOPLASMS; PAIN; SENSORY RECEPTOR CELLS; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84930608070     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2015.07.009     Document Type: Erratum

References (33)

1. Agarwal N., Offermanns S., Kuner R. Conditional gene deletion in primary nociceptive neurons of trigeminal ganglia and dorsal root ganglia. Genesis 2004, 38:122-129.
2. Ambati B.K., Nozaki M., Singh N., Takeda A., Jani P.D., Suthar T., Albuquerque R.J., Richter E., Sakurai E., Newcomb M.T., et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature 2006, 443:993-997.
3. Bae D.G., Kim T.D., Li G., Yoon W.H., Chae C.B. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis. Clin. Cancer Res. 2005, 11:2651-2661.
4. Bais C., Wu X., Yao J., Yang S., Crawford Y., McCutcheon K., Tan C., Kolumam G., Vernes J.M., Eastham-Anderson J., et al. PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell 2010, 141:166-177.
5. Basbaum A.I., Bautista D.M., Scherrer G., Julius D. Cellular and molecular mechanisms of pain. Cell 2009, 139:267-284.
6. Bloom A.P., Jimenez-Andrade J.M., Taylor R.N., Castañeda-Corral G., Kaczmarska M.J., Freeman K.T., Coughlin K.A., Ghilardi J.R., Kuskowski M.A., Mantyh P.W. Breast cancer-induced bone remodeling, skeletal pain, and sprouting of sensory nerve fibers. J.Pain 2011, 12:698-711.
7. Brierley S.M., Hughes P.A., Page A.J., Kwan K.Y., Martin C.M., O'Donnell T.A., Cooper N.J., Harrington A.M., Adam B., Liebregts T., et al. The ion channel TRPA1 is required for normal mechanosensation and is modulated by algesic stimuli. Gastroenterology 2009, 137:2084-2095.e3.
8. Cain D.M., Wacnik P.W., Turner M., Wendelschafer-Crabb G., Kennedy W.R., Wilcox G.L., Simone D.A. Functional interactions between tumor and peripheral nerve: changes in excitability and morphology of primary afferent fibers in a murine model of cancer pain. J.Neurosci. 2001, 21:9367-9376.
9. Carmeliet P., Moons L., Luttun A., Vincenti V., Compernolle V., De Mol M., Wu Y., Bono F., Devy L., Beck H., et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 2001, 7:575-583.
10. Chang Y.T., Chang M.C., Wei S.C., Tien Y.W., Hsu C., Liang P.C., Tsao P.N., Jan I.S., Wong J.M. Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer. Pancreas 2008, 37:145-150.
11. Constantin C.E., Mair N., Sailer C.A., Andratsch M., Xu Z.Z., Blumer M.J., Scherbakov N., Davis J.B., Bluethmann H., Ji R.R., Kress M. Endogenous tumor necrosis factor alpha (TNFalpha) requires TNF receptor type 2 to generate heat hyperalgesia in a mouse cancer model. J.Neurosci. 2008, 28:5072-5081.
12. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat. Med. 2003, 9:669-676.
13. Fischer C., Jonckx B., Mazzone M., Zacchigna S., Loges S., Pattarini L., Chorianopoulos E., Liesenborghs L., Koch M., De Mol M., et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007, 131:463-475.
14. Fischer C., Mazzone M., Jonckx B., Carmeliet P. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?. Nat. Rev. Cancer 2008, 8:942-956.
15. Garassino M.C., Hollander L., Torri V. Bevacizumab for non-small-cell lung cancer. N.Engl. J. Med. 2007, 356:1373-1375.
16. Hiratsuka S., Minowa O., Kuno J., Noda T., Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl. Acad. Sci. USA 1998, 95:9349-9354.
17. Huang J., Tan Y., Tang Q., Liu X., Guan X., Feng Z., Zhu J. A high-affinity human/mouse cross-reactive monoclonal antibody, specific for VEGFR-2 linear and conformational epitopes. Cytotechnology 2010, 62:61-71.
18. Hucho T., Levine J.D. Signaling pathways in sensitization: toward a nociceptor cell biology. Neuron 2007, 55:365-376.
19. Jarvis M.F., Burgard E.C., McGaraughty S., Honore P., Lynch K., Brennan T.J., Subieta A., Van Biesen T., Cartmell J., Bianchi B., et al. A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat. Proc. Natl. Acad. Sci. USA 2002, 99:17179-17184.
20. Johnson D.H., Fehrenbacher L., Novotny W.F., Herbst R.S., Nemunaitis J.J., Jablons D.M., Langer C.J., DeVore R.F., Gaudreault J., Damico L.A., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J.Clin. Oncol. 2004, 22:2184-2191.
21. Kut C., Mac Gabhann F., Popel A.S. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br. J. Cancer 2007, 97:978-985.
22. Luo C., Gangadharan V., Bali K.K., Xie R.G., Agarwal N., Kurejova M., Tappe-Theodor A., Tegeder I., Feil S., Lewin G., et al. Presynaptically localized cyclic GMP-dependent protein kinase 1 is a key determinant of spinal synaptic potentiation and pain hypersensitivity. PLoS Biol. 2012, 10:e1001283.
23. Malik-Hall M., Dina O.A., Levine J.D. Primary afferent nociceptor mechanisms mediating NGF-induced mechanical hyperalgesia. Eur. J. Neurosci. 2005, 21:3387-3394.
24. Mantyh P. Bone cancer pain: causes, consequences, and therapeutic opportunities. Pain 2013, 154(Suppl 1):S54-S62.
25. Mantyh P.W., Koltzenburg M., Mendell L.M., Tive L., Shelton D.L. Antagonism of nerve growth factor-TrkA signaling and the relief of pain. Anesthesiology 2011, 115:189-204.
26. Olsson A.K., Dimberg A., Kreuger J., Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat. Rev. Mol. Cell Biol. 2006, 7:359-371.
27. Schweizerhof M., Stösser S., Kurejova M., Njoo C., Gangadharan V., Agarwal N., Schmelz M., Bali K.K., Michalski C.W., Brugger S., et al. Hematopoietic colony-stimulating factors mediate tumor-nerve interactions and bone cancer pain. Nat. Med. 2009, 15:802-807.
28. Srivastava K., Hu J., Korn C., Savant S., Teichert M., Kapel S.S., Jugold M., Besemfelder E., Thomas M., Pasparakis M., Augustin H.G. Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth. Cancer Cell 2014, 26:880-895.
29. Stefater J.A., Lewkowich I., Rao S., Mariggi G., Carpenter A.C., Burr A.R., Fan J., Ajima R., Molkentin J.D., Williams B.O., et al. Regulation of angiogenesis by a non-canonical Wnt-Flt1 pathway in myeloid cells. Nature 2011, 474:511-515.
30. Van de Veire S., Stalmans I., Heindryckx F., Oura H., Tijeras-Raballand A., Schmidt T., Loges S., Albrecht I., Jonckx B., Vinckier S., et al. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 2010, 141:178-190.
31. Wacnik P.W., Eikmeier L.J., Ruggles T.R., Ramnaraine M.L., Walcheck B.K., Beitz A.J., Wilcox G.L. Functional interactions between tumor and peripheral nerve: morphology, algogen identification, and behavioral characterization of a new murine model of cancer pain. J.Neurosci. 2001, 21:9355-9366.
32. Zhu Y., Tibensky I., Schmidt J., Ryschich E., Märten A. Interferon-alpha enhances antitumor effect of chemotherapy in an orthotopic mouse model for pancreatic adenocarcinoma. J.Immunother. 2008, 31:599-606.
33. Zurborg S., Piszczek A., Martínez C., Hublitz P., Al Banchaabouchi M., Moreira P., Perlas E., Heppenstall P.A. Generation and characterization of an Advillin-Cre driver mouse line. Mol. Pain 2011, 7:66.